Sign in
Not yet taking people in United StatesPhase 3

Fighting Osteoporosis With Risedronate Co-Therapy During Incretin

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
96 people, planned
Starts
Jun 2027
Expected to end
Nov 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tirzepatide
  • Risedronate
  • Placebo
Record updated
17 November 2026

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • BMI≥30 or 27.0-29.9 kg/m2 plus one weight related co-morbidity
  • Weight stability (within 5% in past 3 months)
  • Community dwelling
  • English speaking
  • Able to attend regular in person appointments, willingness to take tirzepatide and risedronate medication, and willing to provide informed consent

Who cannot take part

  • >1 fall (injurious or non-injurious) in past year or prior fragility fracture
  • Osteoporosis (self-report, medication use, or T-score ≤ -2.5 on hip or spine DXA scan)
  • Use of oral corticosteroids (>5 d/month in past 3 months), use of incretin analog (GLP1Ra or dual agonist) in past 24 months, use of any AOM or prescription osteoporosis medication in last 12 months, history of intolerance or adverse reaction to GLP1Ra (other incretin analog) or bisphosphonate, concomitant use of insulin secretagogues or insulin
  • Eating disorder in past 5 years
  • Weight >450 lbs (DXA limit)
  • Disordered alcohol or substance use

Where in United States

  • Atrium Health Wake Forest BaptistWinston-Salem, United StatesContact: Kim KennedyNot yet recruiting

About the trial

What the trial wants to find out

Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.

The 2 groups in the trial

  • Tirzepatide Plus RisedronateTreatment being tested

    Treatment: Tirzepatide and Risedronate

  • Tirzepatide Plus PlaceboExisting treatment, for comparison

    Treatment: Tirzepatide and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bisphosphonate Co-Therapy to Preserve Musculoskeletal Health in Older Adults Using Tirzepatide
Record updated
17 November 2026